Beyond the badge, exploring the intersection of high stakes FDA regulation, clinical trial compliance, and strategic advisory grounded in real world inspection experience.
Insights drawn from real world FDA BIMO inspection experience and global clinical trial oversight.
An inside perspective on how FDA BIMO inspections are conducted, where organizations fall short, and how sponsors and CROs can strengthen inspection readiness before regulatory findings occur.
A deep dive into why GxP compliance is not just procedural, but foundational to patient safety, data integrity, and regulatory trust through the lens of FDA inspection experience.
Read More arrow_forward
Navigating the transition from regulatory enforcement to advisory, and how inspection insight can be translated into strategic guidance for sponsors and CROs.
Read More arrow_forward
A practical perspective for professionals transitioning into consulting, maintaining regulatory integrity while delivering high value advisory services.
Read More arrow_forward
Why quality by design is not optional, but essential for maintaining compliance, avoiding delays, and ensuring inspection readiness in clinical development.
Read More arrow_forward
How to develop an inspection mindset within your team, identifying compliance gaps early and strengthening readiness before regulatory review.
Read More arrow_forwardWhat sponsors should expect during a BIMO inspection, how to prepare effectively, and where most organizations fall short.
Read More arrow_forwardHow unclear protocols, inconsistent documentation, and oversight gaps create avoidable regulatory risk.
Read More arrow_forwardA closer look at how protocol clarity and SOP alignment directly impact compliance outcomes during FDA inspections.
Read More arrow_forwardSubscribe to receive monthly briefings on regulatory shifts and advisory insights directly from the desk of Sereen Murray-Morgan.